Total Liabilities Summary of Transgene SA

Transgene SA's latest annual total liabilities in 2023 was 26.51 Million EUR , down -7.27% from previous year.
Transgene SA's latest quarterly total liabilities in 2024 Q2 was 48.16 Million EUR , down 0.0% from previous quarter.
Transgene SA reported annual total liabilities of 28.59 Million EUR in 2022, down -17.42% from previous year.
Transgene SA reported annual total liabilities of 34.62 Million EUR in 2021, down -1.63% from previous year.
Transgene SA reported quarterly total liabilities of 27.59 Million EUR for 2023 Q1, down -3.51% from previous quarter.
Transgene SA reported quarterly total liabilities of 26.51 Million EUR for 2023 Q4, down -10.43% from previous quarter.

Annual Total Liabilities Chart of Transgene SA (2023 - 1997)

Historical Annual Total Liabilities of Transgene SA (2023 - 1997)

Year	Total Liabilities	Total Liabilities Growth
2023	26.51 Million EUR	-7.27%
2022	28.59 Million EUR	-17.42%
2021	34.62 Million EUR	-1.63%
2020	35.2 Million EUR	-29.28%
2019	49.78 Million EUR	-30.71%
2018	71.84 Million EUR	-1.29%
2017	72.78 Million EUR	-4.79%
2016	76.44 Million EUR	2.86%
2015	74.32 Million EUR	7.54%
2014	69.11 Million EUR	-0.16%
2013	69.22 Million EUR	13.7%
2012	60.88 Million EUR	16.71%
2011	52.16 Million EUR	30.2%
2010	40.06 Million EUR	33.11%
2009	30.1 Million EUR	-7.16%
2008	32.42 Million EUR	86.58%
2007	17.37 Million EUR	27.54%
2006	13.62 Million EUR	0.0%
2004	11.26 Million EUR	-0.27%
2003	11.29 Million EUR	-3.2%
2002	11.67 Million EUR	-8.71%
2001	12.78 Million EUR	-2.76%
2000	13.15 Million EUR	15.22%
1999	11.41 Million EUR	0.77%
1998	11.32 Million EUR	19.61%
1997	9.46 Million EUR	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q2	48.16 Million EUR	0.0%
2023 Q1	27.59 Million EUR	-3.51%
2023 Q4	26.51 Million EUR	-10.43%
2023 Q2	27.59 Million EUR	0.0%
2023 Q3	29.6 Million EUR	7.3%
2023 FY	26.51 Million EUR	-7.27%
2022 Q3	28.59 Million EUR	-8.69%
2022 FY	28.59 Million EUR	-17.42%
2022 Q4	28.59 Million EUR	0.0%
2022 Q2	31.31 Million EUR	0.0%
2022 Q1	31.31 Million EUR	-9.56%
2021 Q2	34.27 Million EUR	0.0%
2021 FY	34.62 Million EUR	-1.63%
2021 Q1	34.27 Million EUR	-2.63%
2021 Q3	34.62 Million EUR	1.02%
2021 Q4	34.62 Million EUR	0.0%
2020 Q1	45.45 Million EUR	-8.69%
2020 Q2	45.45 Million EUR	0.0%
2020 Q3	34.73 Million EUR	-23.58%
2020 FY	35.2 Million EUR	-29.28%
2020 Q4	35.2 Million EUR	1.34%
2019 Q2	72.17 Million EUR	0.0%
2019 FY	49.78 Million EUR	-30.71%
2019 Q3	49.78 Million EUR	-31.03%
2019 Q4	49.78 Million EUR	0.0%
2019 Q1	72.17 Million EUR	0.46%
2018 FY	71.84 Million EUR	-1.29%
2018 Q2	71.48 Million EUR	0.0%
2018 Q1	71.48 Million EUR	-1.78%
2018 Q4	71.84 Million EUR	-0.15%
2018 Q3	71.94 Million EUR	0.65%
2017 Q4	72.78 Million EUR	0.0%
2017 Q2	73.32 Million EUR	0.0%
2017 FY	72.78 Million EUR	-4.79%
2017 Q3	72.78 Million EUR	-0.74%
2017 Q1	73.32 Million EUR	-4.08%
2016 FY	76.44 Million EUR	2.86%
2016 Q3	76.44 Million EUR	-4.51%
2016 Q2	80.06 Million EUR	0.0%
2016 Q1	80.06 Million EUR	7.72%
2016 Q4	76.44 Million EUR	0.0%
2015 Q2	84.1 Million EUR	0.0%
2015 FY	74.32 Million EUR	7.54%
2015 Q4	74.32 Million EUR	0.0%
2015 Q3	74.32 Million EUR	-11.63%
2015 Q1	84.1 Million EUR	21.68%
2014 Q4	69.11 Million EUR	0.0%
2014 Q3	69.11 Million EUR	-15.65%
2014 FY	69.11 Million EUR	-0.16%
2014 Q2	81.94 Million EUR	0.0%
2014 Q1	81.94 Million EUR	18.36%
2013 Q1	68.1 Million EUR	11.85%
2013 FY	69.22 Million EUR	13.7%
2013 Q4	69.22 Million EUR	0.0%
2013 Q3	69.22 Million EUR	1.65%
2013 Q2	68.1 Million EUR	0.0%
2012 FY	60.88 Million EUR	16.71%
2012 Q4	60.88 Million EUR	-2.18%
2012 Q2	60.47 Million EUR	0.0%
2012 Q3	62.24 Million EUR	2.93%
2011 Q2	44.93 Million EUR	0.0%
2011 Q4	52.16 Million EUR	0.0%
2011 FY	52.16 Million EUR	30.2%
2010 FY	40.06 Million EUR	33.11%
2010 Q2	36.5 Million EUR	0.0%
2010 Q4	40.06 Million EUR	0.0%
2009 Q2	30.31 Million EUR	0.0%
2009 FY	30.1 Million EUR	-7.16%
2009 Q4	30.1 Million EUR	0.0%
2008 FY	32.42 Million EUR	86.58%
2008 Q4	32.42 Million EUR	0.0%
2007 FY	17.37 Million EUR	27.54%
2006 FY	13.62 Million EUR	0.0%
2005 Q2	10.13 Million EUR	0.0%
2004 FY	11.26 Million EUR	-0.27%
2004 Q4	11.26 Million EUR	0.0%
2004 Q2	10.8 Million EUR	-1.76%
2004 Q1	11 Million EUR	-2.65%
2003 Q3	10.42 Million EUR	-5.05%
2003 Q4	11.29 Million EUR	8.41%
2003 Q2	10.97 Million EUR	0.8%
2003 FY	11.29 Million EUR	-3.2%
2003 Q1	10.88 Million EUR	-6.71%
2002 Q4	11.67 Million EUR	11.58%
2002 Q2	11.66 Million EUR	0.4%
2002 Q1	11.62 Million EUR	-9.12%
2002 FY	11.67 Million EUR	-8.71%
2002 Q3	10.46 Million EUR	-10.33%
2001 Q3	12.32 Million EUR	-10.43%
2001 Q4	12.78 Million EUR	3.75%
2001 FY	12.78 Million EUR	-2.76%
2001 Q1	12.62 Million EUR	-4.01%
2001 Q2	13.75 Million EUR	9.0%
2000 Q1	12.04 Million EUR	5.55%
2000 FY	13.15 Million EUR	15.22%
2000 Q3	11.83 Million EUR	-4.06%
2000 Q4	13.15 Million EUR	11.08%
2000 Q2	12.33 Million EUR	2.43%
1999 FY	11.41 Million EUR	0.77%
1999 Q4	11.41 Million EUR	0.0%
1998 FY	11.32 Million EUR	19.61%
1998 Q4	11.32 Million EUR	0.0%
1997 FY	9.46 Million EUR	0.0%

Peer Total Liabilities Comparison of Transgene SA

Name	Total Liabilities	Total Liabilities Difference
ABIONYX Pharma SA	6.91 Million EUR	-283.637%
ABIVAX Société Anonyme	131.05 Million EUR	79.766%
Adocia SA	31.87 Million EUR	16.796%
Aelis Farma SA	13.08 Million EUR	-102.729%
Biophytis S.A.	15.84 Million EUR	-67.31%
Advicenne S.A.	24.37 Million EUR	-8.779%
genOway Société anonyme	14.45 Million EUR	-83.388%
IntegraGen SA	5.97 Million EUR	-343.443%
Medesis Pharma S.A.	6.42 Million EUR	-312.64%
Neovacs S.A.	3.71 Million EUR	-614.335%
NFL Biosciences SA	3.62 Million EUR	-632.376%
Plant Advanced Technologies SA	6.78 Million EUR	-290.971%
Quantum Genomics Société Anonyme	3.31 Million EUR	-701.092%
Sensorion SA	13.22 Million EUR	-100.472%
Theranexus Société Anonyme	5.01 Million EUR	-428.628%
TME Pharma N.V.	2.78 Million EUR	-852.136%
Valbiotis SA	13.7 Million EUR	-93.442%
TheraVet SA	1.48 Million EUR	-1685.665%
Valerio Therapeutics Société anonyme	20.46 Million EUR	-29.553%
DBV Technologies S.A.	38.74 Million USD	31.561%
Genfit S.A.	105.92 Million EUR	74.965%
GeNeuro SA	20.13 Million EUR	-31.664%
Innate Pharma S.A.	132.29 Million EUR	79.956%
Inventiva S.A.	101.59 Million EUR	73.899%
MaaT Pharma SA	22.46 Million EUR	-18.037%
MedinCell S.A.	77.77 Million EUR	65.903%
Nanobiotix S.A.	95.74 Million EUR	72.303%
OSE Immunotherapeutics SA	59.07 Million EUR	55.116%
Poxel S.A.	53.9 Million EUR	50.804%
GenSight Biologics S.A.	34.72 Million EUR	23.642%
Valneva SE	341.14 Million EUR	92.227%

Global Stocks Search

Transgene SA (TNG.PA)

Total Liabilities Summary of Transgene SA

Annual Total Liabilities Chart of Transgene SA (2023 - 1997)

Historical Annual Total Liabilities of Transgene SA (2023 - 1997)

Peer Total Liabilities Comparison of Transgene SA